Formally yes, practically restrained. Spravato (esketamine) is legal and assessed in Sweden, but the NT Council — the body that advises all 21 regions on new therapies — recommends "strongly restrained" (kraftigt återhållsam) use, and each region decides its own funding. Sweden never rejected Spravato the way England or Norway did; it told the regions to hold back, which produces a route that is real but deliberately narrow — in practice reserved for patients who have tried roughly four other treatment alternatives. This page covers what that means in practice, who qualifies, what you pay, and what to do if your region says no; the eligibility decision itself always sits with a clinician, and you can begin orienting yourself with our eligibility check.
What is covered
The NT Council's recommendation on Spravato — first issued 30 June 2021, revised 6 November 2024 — advises the regions to use the spray with strong restraint, citing documented uncertainty about long-term benefit and side effects relative to price. Two structural facts follow from this, and they decide what you can actually get:
- Funding is regional. The NT Council advises; each of the 21 regions decides. Some regions have published local care routines for Spravato in treatment-resistant depression — Region Skåne, for example, maintains a detailed clinical protocol — while others fund little or none. The same diagnosis can meet a different answer in a different county.
- Delivery is specialist-only. Spravato is a clinic-administered (rekvisition) medicine given in specialist psychiatry with post-dose observation, never dispensed for home use.
What is not covered: off-label racemic ketamine has no national funding decision in Sweden — there is no Norwegian-style pathway here — so private ketamine treatment is entirely self-pay.
Who qualifies
There is no published national criteria list of the Polish or Swiss kind; the restraint recommendation itself sets the bar. In practice Spravato only becomes relevant after a run of better-documented options — roughly four treatment alternatives, counting antidepressants, augmentation and, where appropriate, ECT — has been tried and failed in specialist psychiatry.
The practical currency is a written treatment history: every antidepressant and augmentation tried in the current episode, with dose, duration and outcome. In a system built on restraint, that document is your case — expect it to be scrutinised against the roughly-four-alternatives bar.
Who decides and how to apply
Ask your vårdcentral for a referral to specialist psychiatry, or approach a psychiatric clinic directly where your region allows self-referral (egenremiss). The assessment chain — referral, specialist evaluation, internal decision — runs inside specialist psychiatry: the NT Council advises, your region funds or does not, and the treating clinic's protocol does the rest. Even in funding regions, volumes are small and clinics few, so expect months rather than weeks.
To see who is listed, browse providers in Sweden; for the full picture of every legal route in the country — including the unusually strong trial scene — see our Sweden access guide.
What it costs you
Where your region funds treatment, you pay ordinary patient fees that count toward the national high-cost ceiling (högkostnadsskydd) — public specialist care pricing, not the drug's list price.
The self-pay comparison is the private ketamine market, concentrated in Stockholm: roughly 4,500–5,000 SEK per infusion, with a typical induction course of six infusions bringing the medicine cost alone to around 27,000–30,000 SEK before assessment fees. Private treatment is not covered by regional funding and does not count toward the high-cost ceiling.
If you do not qualify
If your region says no — or the restraint bar is out of reach — the honest fallbacks are:
- A second specialist opinion or a documented individual case. Regional decisions are not uniform, and a specialist willing to argue your documented history is the strongest asset you can have.
- Off-label ketamine. Some public specialist settings use ketamine within hospital psychiatry at the treating department's discretion — a conversation to have if you are already in specialist care — and the private Stockholm market treats at the self-pay prices above. Screening quality varies; see our clinic-choice guide.
- Clinical trials are free by definition, and Sweden is one of the better European countries for joining a psilocybin trial — studies are recruiting in Stockholm, Gothenburg, Uppsala, Örebro and Lund in July 2026. See the trials guide for how participation works.
Frequently asked questions
Is Spravato reimbursed in Sweden?
Formally it can be — Sweden assessed it rather than rejecting it — but the NT Council recommends strongly restrained use (recommendation revised 6 November 2024), in practice after roughly four failed treatment alternatives, and each of the 21 regions decides whether to fund it. Whether you are covered depends on your region's stance and your documented history.
Why does availability depend on where I live?
Sweden's 21 regions each make their own funding decisions; the NT Council only advises them. Some regions have published Spravato care routines, others fund little or none. If your region says no, options are a second specialist opinion, a documented individual case, or the research route.
What does "strongly restrained" actually mean for me?
That Spravato is treated as a late option, not a standard one: the recommendation reflects documented uncertainty about long-term benefit and side effects relative to price, so clinics reserve it for patients with roughly four failed alternatives on paper. How Sweden's restraint compares with its neighbours is mapped in our Europe-wide reimbursement map.
Does the high-cost ceiling cover private ketamine?
No. Public specialist care, including regionally funded Spravato, falls under ordinary patient fees and the high-cost ceiling; private ketamine clinics and anything self-paid sit outside it. Ask for the full course price in writing before starting.
Sources
- Samverkanläkemedel (NT Council): Spravato (esketamin) — recommendation of 30 June 2021, revised 6 November 2024
- Läkartidningen: NT-rådet rekommenderar kraftigt återhållsam användning av Spravato (November 2021)
- TLV: Health-economic assessment of Spravato (esketamine) nasal spray (2020, PDF)
- Region Skåne: Spravato (esketamin) vid terapiresistent depression — regional care routine (PDF)
- Blossom: Medical access in Sweden
- Reimbursement Pathways for Psychedelic Therapies in Europe — Magnetar Access × Blossom (2025)
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and reimbursement rules change; always verify current requirements with your insurer and discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.